The filoviruses are NIAID/CDC Category A biodefense pathogens that cause severe and rapidly progressing hemorrhagic fever with 50-90% human lethality. There are currently no FDA-approved vaccines or therapies for filovirus infection. Among the filoviruses, the Zaire Ebola virus species (EBOV) has been most extensively characterized. However, outbreaks ofthe Sudan Ebola virus species (SUDV) and Marburg virus (MARV) have been occurring with increased frequency and can be just as lethal as EBOV. Further, the pathogenic Bundibugyo Ebola virus species (BDBV) re-emerged in 2012 with increased lethality. Immunotherapy was recently demonstrated to provide post-exposure protection to EBOV challenge in nonhuman primates (NHPs). For MARV, convalescent sera from immunized NHPs can provide similar protection, suggesting that immunotherapy for all filoviruses will be tractable in humans. A robust pipeline of monoclonal antibodies (mAbs) targeting EBOV exists and will be developed in Project 1, but the pipeline for SUDV and MARV mAbs is less complete. Not a single SUDV or MARV mAb or mAb cocktail therapy has been evaluated in NHPs. Currently, there are no neutralizing BDBV mAbs. The goal of Project 2 is to fill these gaps in the filovirus therapeutic mAb portfolio. Among consortium investigators, a total of 216 murine mAbs against SUDV or MARV are available but have not been completely characterized;we will develop these mAbs and evaluate them for protection in rodent models and NHPs. In addition, we will identify new SUDV and MARV mAbs from human survivors of infection from outbreaks in Uganda, especially those in 2012. The consortium investigators have unprecedented access to four separate survivor cohorts of SUDV and MARV infection, and have demonstrated recently that neutralizing mAbs exist in peripheral blood of survivors. In addition, we will identify and characterize new anti-BDBV and broadly reactive anti-filovirus mAbs. Preliminary ELISA studies indicate that antibodies with cross-reactivity for the envelope glycoprotein (GP) from SUDV, BDBV and (in some cases) EBOV exist in peripheral blood of survivors who have been exposed to only a single filovirus species. We will use human hybridoma and antibody phage display technologies to screen the lymphocytes of survivors of filovirus infection for new BDBV and cross neutralizing filovirus mAbs. The most promising candidates will be further evaluated in rodent and nonhuman primate challenge models. The end-point of this work will be a robust pipeline of mAbs for these understudied and re-emerging filoviruses.

Public Health Relevance

The filoviruses are highly pathogenic viruses that cause rapidly progressing hemorrhagic fever. There are currently no FDA approved therapies or vaccines to treat filovirus infection. The goal of this work is to develop therapeutic monoclonal antibodies that are effective against several ofthe most pathogenic filoviruses, as well as antibodies that are effective against more than one strain of filovirus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109762-01
Application #
8654210
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
2014-03-15
Project End
2019-02-28
Budget Start
2014-03-15
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,015,070
Indirect Cost
$140,164
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Holtsberg, Frederick W; Shulenin, Sergey; Vu, Hong et al. (2016) Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J Virol 90:266-78
Wec, Anna Z; Nyakatura, Elisabeth K; Herbert, Andrew S et al. (2016) A ""Trojan horse"" bispecific antibody strategy for broad protection against ebolaviruses. Science :
Pallesen, Jesper; Murin, Charles D; de Val, Natalia et al. (2016) Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol 1:16128
Frei, Julia C; Nyakatura, Elisabeth K; Zak, Samantha E et al. (2016) Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci Rep 6:19193
Natesan, Mohan; Jensen, Stig M; Keasey, Sarah L et al. (2016) Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Clin Vaccine Immunol 23:717-24
Qiu, Xiangguo; Audet, Jonathan; Lv, Ming et al. (2016) Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med 8:329ra33
Bornholdt, Zachary A; Turner, Hannah L; Murin, Charles D et al. (2016) Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351:1078-83
Goba, Augustine; Khan, S Humarr; Fonnie, Mbalu et al. (2016) An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. J Infect Dis 214:S110-S121
Robinson, James E; Hastie, Kathryn M; Cross, Robert W et al. (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7:11544
Zeitlin, Larry; Whaley, Kevin J; Olinger, Gene G et al. (2016) Antibody therapeutics for Ebola virus disease. Curr Opin Virol 17:45-9

Showing the most recent 10 out of 27 publications